Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Substantial Medicare savings may result if insurers cover 'artificial pancreas' sooner for diabetes patients. Health Aff (Millwood) 2012 Aug;31(8):1822-9

Date

08/08/2012

Pubmed ID

22869661

DOI

10.1377/hlthaff.2011.1052

Abstract

Technologies to improve diabetes care have advanced considerably with the introduction of the insulin pump and continuous glucose monitoring. These two technologies are now being joined and enhanced to create an artificial pancreas. The current study models the impact of the artificial pancreas on clinical results and costs over time, based on early results from clinical trials. The modeling shows that insurers' coverage of the cost of an artificial pancreas at a relatively early point in the life of a patient with diabetes would greatly reduce future complications of the disease and spending needed to treat such complications. Projected Medicare savings are $937 million in nominal dollars after twenty-five years. The results of this analysis support conducting a more comprehensive trial to assess the long-term impact of the artificial pancreas on glucose levels and the technology's related costs.

Author List

O'Grady MJ, John P, Winn A

Author

Aaron Winn PhD Assistant Professor in the School of Pharmacy Administration department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Adult
Cost Savings
Diabetes Mellitus
Humans
Insurance Coverage
Insurance, Health
Medicare
Middle Aged
Models, Theoretical
Pancreas, Artificial
United States
jenkins-FCD Prod-482 91ad8a360b6da540234915ea01ff80e38bfdb40a